These findings suggest that targeting PCBP2 could not only inhibit tumor progression but also enhance immunotherapy efficacy, highlighting the need for further investigation into its broader regulatory functions in prostate cancer immunity. The gene discussed is PCBP2; the disease is neoplasm.